▟ Vinebot intrinsic value, daily

← back

RMD ResMed

healthcare · valued with opus medium conviction · deep-dived 2026-11-10

STRONG BUY
Intrinsic value$200.36
Price (at call)$235.74
Margin of safety -15.0%
vs market (rating basis) +32.2%

Sleep apnea duopoly leader with recurring mask revenue; fairly priced unless GLP-1 fears come true.

The story

ResMed is the global leader in CPAP devices and masks for sleep apnea. Its moat comes from a large installed base, recurring mask and accessory resupply revenue, and a connected-device and software ecosystem (AirView, myAir, Brightree/MatrixCare) that ties it into payer and DME workflows. Philips' recall handed ResMed share and pricing power, and fears that GLP-1 drugs would shrink demand have so far not shown up in patient flow. The company is a maturing, highly profitable franchise with a long runway, because sleep apnea remains heavily underdiagnosed worldwide.

I set growth at 8%, a bit below the roughly 10% five-year CAGR, to reflect GLP-1 drag and Philips' gradual return to the US market. I put the margin at 33%, just under the current 34.7% peak, because competition will likely erode some of the post-recall pricing. The reported sales-to-capital of 0.79 is held down by acquisition goodwill, while incremental capital needs are light (capex is about 3% of sales), so I use 1.6. A 10-year horizon fits a durable duopoly with an underpenetrated market, and these drivers come out close to the current market price instead of the baseline's 140.

Value drivers

Revenue growth (Y1)8.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin33.0%
Years to target margin3
Sales-to-capital1.60
Beta0.85
Failure probability1.0%
Cost of capital (WACC)8.6%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF11.81B
PV of terminal value15.85B
Equity value28.18B
÷ shares → per share$200.36

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 6.19B 8.0% 34.1% 1.68B 286.63M 1.39B 1.28B
2 6.66B 7.5% 33.6% 1.77B 290.22M 1.48B 1.26B
3 7.12B 7.0% 33.0% 1.87B 291.18M 1.57B 1.23B
4 7.58B 6.5% 33.0% 1.99B 289.31M 1.70B 1.22B
5 8.04B 6.0% 33.0% 2.11B 284.42M 1.82B 1.20B
6 8.48B 5.5% 33.0% 2.22B 276.36M 1.94B 1.18B
7 8.91B 5.0% 33.0% 2.33B 265.05M 2.07B 1.16B
8 9.31B 4.5% 33.0% 2.44B 250.47M 2.19B 1.13B
9 9.68B 4.0% 33.0% 2.53B 232.66M 2.30B 1.09B
10 10.02B 3.5% 33.0% 2.62B 211.72M 2.41B 1.06B

Key risks

  • GLP-1 drugs reduce how many patients get diagnosed and treated, or how long they stay on therapy
  • Philips' full return to the US market pressures device pricing and share
  • Reimbursement cuts or competitive bidding at CMS and international payers

Catalysts

  • Real-world data showing GLP-1 users start and stay on PAP therapy at higher rates
  • Gross margin gains from manufacturing efficiencies and mask mix, plus growth in the SaaS segment

History

DatePriceIntrinsicMoSRating
2026-11-10$235.74 $200.36 -15.0% STRONG BUY
2026-09-21$224.99 $127.79 -43.2% HOLD
2026-07-31$208.56 $163.82 -21.4% STRONG BUY
2026-06-23$191.26 $173.34 -9.4% STRONG BUY